Abstract
Background: Blocking the PD1-PD-L1 interaction has been shown to stimulate anti-tumour responses. Although antibody-based drugs targeting either PD-1 or PD-L1 are approved, small molecule inhibitors of PD-L1 are currently in development. A subset of these small molecule inhibitors induce the loss of cell surface PD-L1 in a time- and concentration-dependent manner. INCB090244 is a small molecule that has previously been shown to bind to PD-L1 and disrupt the PD-L1/PD-1 interaction.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
